ALX Oncology Holdings Inc. (ALXO) News

ALX Oncology Holdings Inc. (ALXO): $8.23

0.14 (+1.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ALXO News Items

ALXO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALXO News Highlights

  • For ALXO, its 30 day story count is now at 2.
  • Over the past 2 days, the trend for ALXO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ALXO News From Around the Web

Below are the latest news stories about Alx Oncology Holdings Inc that investors may wish to consider to help them evaluate ALXO as an investment opportunity.

3 ‘Strong Buy’ Small-Cap Stocks That Are Too Cheap to Ignore

How do you make sense of the current market conditions? We came off a strong bull year for stocks with the worst January in a long time – but the month ended, and February started with the best two-day action since April 2000. And in a quirk, that investors should note, small-cap stocks are showing strong signs of being heavily oversold. Small-caps took a harder hit in January’s swoon than the market giants, and according to JPMorgan's Chief Global Markets Strategist Marko Kolanovic, investors s

Yahoo | February 4, 2022

HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ...

Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.

Yahoo | February 2, 2022

ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

Yahoo | January 28, 2022

ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer

The FDA has granted Orphan Drug Designation to ALX Oncology Holdings Inc's (NASDAQ: ALXO) evorpacept for gastric cancer and gastroesophageal junction cancer. In ASPEN-01, patients with >2L HER2 positive gastric (n=18) treated with evorpacept combined with trastuzumab plus ramucirumab and paclitaxel demonstrated an initial objective response rate of 72.2% with a median duration of response of 14.8 months and a median overall survival of 17.1 months. Related content: Benzinga's Full FDA Calendar.

Yahoo | January 28, 2022

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer (collectively “GC”). “Receiving or

Yahoo | January 27, 2022

ALX Oncology Holdings (ALXO) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

New Strong Sell Stocks for January 19th

ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022

Yahoo | January 19, 2022

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022. “2021 was a year of substantial corporate and clinical accomplishments for ALX Oncology. We initiated numerous clinical trials, including two Phase 2 trials in head and neck squamous cell c

Yahoo | January 10, 2022

ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will virtually present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 am ET. A live webcast of the presentation is available here a

Yahoo | January 4, 2022

ALX Oncology (NASDAQ:ALXO) Shares Gap Down to $22.91

ALX Oncology Holdings Inc. (NASDAQ:ALXO) shares gapped down prior to trading on Wednesday . The stock had previously closed at $22.91, but opened at $21.68. ALX Oncology shares last traded at $20.84, with a volume of 3,276 shares. A number of equities analysts recently issued reports on the stock. Credit Suisse Group dropped their price []

Dakota Financial News | December 24, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4566 seconds.